Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Morning Bright Light Therapy and Daytime Functioning in University Students (BLIGHT)

29 juin 2026 mis à jour par: Dr YU Cehao, The Hong Kong Polytechnic University

Effects of Morning Bright Light Therapy on Sleep, Alertness, Mood, and Cognition in Healthy University Students: A Randomized Crossover Trial

This study tests whether a week of morning bright light therapy changes how well healthy young adults sleep and how alert, positive, and mentally sharp they feel during the day.

Morning light is the body's main signal for keeping its internal clock and sleep-wake timing on track. Many university students keep irregular hours and spend most of the day indoors, where light is far dimmer than daylight. This study asks whether adding a short, bright morning light session can help.

Each participant takes part for two weeks. For one week they use a bright light box for 30 minutes each morning, shortly after waking; for the other week they keep their usual lighting. The order of the two weeks is decided at random, and each person serves as their own comparison.

Throughout both weeks, sleep is tracked with a wrist-worn Fitbit and a short daily diary. Participants also rate their sleepiness and mood, complete brief computer-based attention and memory tasks, and take part in a short interview at the end about their experience.

The study compares the bright-light week with the usual-light week to see whether morning bright light improves sleep regularity and efficiency, reduces daytime sleepiness, lifts mood, or affects thinking performance. The trial is being conducted in waves; a first wave has completed and a second wave is planned, pending additional funding.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

Background and rationale: Morning light is the principal entraining signal for the human circadian system, acting through melanopsin-containing intrinsically photosensitive retinal ganglion cells that project to the suprachiasmatic nucleus. University students frequently experience irregular sleep-wake schedules and limited daytime light exposure, particularly in cooling-dominant subtropical buildings where occupants keep blinds drawn. Bright light therapy (BLT) is an established treatment for circadian and affective disorders, but its effects on sleep regularity, daytime alertness, mood, and objective cognition in healthy students are less well characterized. This trial evaluates a brief, self-administered morning BLT regimen using a within-subject crossover design.

Design: Single-center, randomized, within-subject (crossover) trial. Each participant completes two consecutive one-week conditions-morning BLT and usual-light control-in counterbalanced order with no washout period. Allocation to condition order (sequence) is randomized, and each participant serves as their own control; all crossover models include condition, period (week), and sequence terms.

Setting and population: Healthy university students residing in shared student housing in Hong Kong. Eligibility is restricted to generally healthy young adults without a diagnosed sleep disorder; sleep quality is screened (Pittsburgh Sleep Quality Index), and individuals with diagnosed insomnia or other relevant conditions are excluded.

Intervention: During the BLT week, participants self-administer a 30-minute session of 10,000 lux (photopic) bright light approximately 30 minutes after waking, using a standard light therapy lamp positioned per manufacturer guidance. The stimulus is characterized in melanopic units (melanopic equivalent daylight illuminance ≈ 8,989 lux). During the control week, participants maintain their usual indoor lighting and morning routine without the lamp.

Assessments: Sleep is monitored continuously with a wrist-worn Fitbit and a daily diary throughout both weeks. Daytime sleepiness and alertness are rated at fixed times of day (Karolinska and Stanford Sleepiness Scales). Mood and affect are assessed with the Positive and Negative Affect Schedule and the Profile of Mood States. A computer-based cognitive battery (Stroop, Flanker, Corsi block-tapping, verbal span) is administered at the end of each condition week. Post-trial semi-structured interviews capture subjective experience and acceptability.

Outcome structure: A small, a priori primary confirmatory outcome family-defined in the approved study protocol on the basis of hypothesized domains rather than observed effects-covers daytime sleepiness, sleep regularity, positive affect, and cognition; remaining measures are secondary or exploratory. Formal outcome-measure definitions are provided in the Outcome Measures module.

Statistical analysis: Outcomes are analyzed with linear mixed-effects models of the form outcome ~ condition + period + sequence + (1 | participant), estimated by REML with Satterthwaite degrees of freedom. Multiplicity is controlled with Holm correction across the primary outcome family. Paired within-person effect sizes (Cohen's dz) accompany model-based estimates, and sensitivity analyses examine period, sequence, and carryover effects.

Conduct in waves: The trial is being conducted in waves. A first wave (33 participants) has completed data collection; a second wave is planned and will commence pending additional funding, so recruitment is currently inactive.

Type d'étude

Interventionnel

Inscription (Estimé)

153

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Hung Hom, Hong Kong
        • Recrutement
        • The Hong Kong Polytechnic University

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Oui

La description

Inclusion Criteria:

  • Enrolled university student
  • Aged 18 years or older
  • Generally healthy, with no diagnosed sleep disorder (sleep quality screened using the Pittsburgh Sleep Quality Index)
  • Residing in shared student housing

Exclusion Criteria:

  • Diagnosed insomnia or other diagnosed sleep disorder
  • Other medical, psychiatric, or neurological condition that could affect sleep, mood, or cognition

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Science basique
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Morning Bright Light Therapy
During this one-week condition, participants self-administer a 30-minute session of 10,000 lux bright light (melanopic equivalent daylight illuminance ≈ 8,989 lux) each morning, approximately 30 minutes after waking, using a standard light therapy lamp positioned per manufacturer guidance.
Self-administered 30-minute session of 10,000 lux (photopic) bright light each morning, approximately 30 minutes after waking, for one week, using a standard 10,000-lux light therapy lamp positioned per manufacturer guidance. Stimulus characterized in melanopic units (melanopic equivalent daylight illuminance ≈ 8,989 lux).
Aucune intervention: Usual Light (Control)
During this one-week condition, participants maintain their usual indoor lighting and morning routine without the light therapy lamp.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Sleep regularity
Délai: Recorded continuously across each 1-week condition (bright-light week and usual-light week).
Regularity of sleep timing derived from wrist-worn Fitbit actigraphy and a daily sleep diary (e.g., day-to-day variability in sleep onset and offset). Condition-week values are compared between the bright-light week and the usual-light week.
Recorded continuously across each 1-week condition (bright-light week and usual-light week).
Daytime sleepiness (Karolinska Sleepiness Scale)
Délai: Assessed daily at fixed times across each 1-week condition (bright-light week and usual-light week).
Subjective daytime sleepiness rated on the 9-point Karolinska Sleepiness Scale (KSS) at fixed times of day. Condition-week values are compared between the bright-light week and the usual-light week.
Assessed daily at fixed times across each 1-week condition (bright-light week and usual-light week).
Positive affect (PANAS Positive Affect subscale)
Délai: End of each 1-week condition (bright-light week and usual-light week).
Positive affect measured with the Positive and Negative Affect Schedule (PANAS) positive-affect subscale. Condition-week scores are compared between the bright-light week and the usual-light week.
End of each 1-week condition (bright-light week and usual-light week).
Cognitive performance (computer-based battery)
Délai: End of each 1-week condition (bright-light week and usual-light week).
Objective cognitive performance on a computer-based battery (Stroop, Flanker, Corsi block-tapping, and verbal span tasks). Condition-week performance is compared between the bright-light week and the usual-light week.
End of each 1-week condition (bright-light week and usual-light week).

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 mai 2024

Achèvement primaire (Estimé)

30 juin 2028

Achèvement de l'étude (Estimé)

30 juin 2028

Dates d'inscription aux études

Première soumission

29 juin 2026

Première soumission répondant aux critères de contrôle qualité

29 juin 2026

Première publication (Réel)

6 juillet 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 juillet 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

29 juin 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • HSEARS20240430005
  • P0050050 (Autre subvention/numéro de financement: University Grants Committee)

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .